SCHEMBL4770907

SCHEMBL4770907

CN(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ LMNA P02545 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.44
▸ SLC22A12 Q96S37 1/20 0.44
▸ NR4A2 P43354 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ TAS2R14 Q9NYV8 2/20 0.42
▸ PTPRC P08575 1/20 0.42
▸ PTPRG P23470 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ RXRA P19793 1/20 0.41
▸ RXRB P28702 1/20 0.41
▸ RXRG P48443 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ SLC6A2 P23975 3/20 0.40
▸ SLC6A4 P31645 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767920 0.81 NR1H4 (0.50) SMN1; SMN2NPSR1LMNAMAPTALDH1A1
SCHEMBL13738402 0.75 RXRA (0.42) TAS2R14MEN1KMT2ARXRARXRB
SCHEMBL8754119 0.75 LMNA (0.49) SMN1; SMN2NPSR1LMNAMAPTALDH1A1
SCHEMBL365480 0.74 SMN1; SMN2 (0.67) SMN1; SMN2NPSR1ALDH1A1SLC22A12NR4A2
SCHEMBL26023444 0.73 RXRA (0.58) MAPTALDH1A1TAS2R14MEN1KMT2A
SCHEMBL10373059 0.73 RXRA (0.58) SMN1; SMN2LMNAALDH1A1NR4A2TAS2R14
SCHEMBL5275323 0.71 POLQ (0.51) SMN1; SMN2LMNAALDH1A1NR4A2TAS2R14
SCHEMBL4772365 0.71 GAA (0.50) SMN1; SMN2NPSR1LMNAMAPTALDH1A1
SCHEMBL21723841 0.71 LMNA (0.41) SMN1; SMN2LMNAMAPTALDH1A1PTPRC
SCHEMBL24776450 0.70 PNMT (0.56) LMNAMAPTALDH1A1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 — — EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 — — US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 — — WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 — — EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 — — US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 SMN1; SMN2 1149/4885NPSR1 4395/4885LMNA 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback